Finally, two bottleneck proteins, FGG and SLC9A3, existing only in the CHD state CePIN, were selected as the targets of Danshensu in the treatment of CHD and as the potential targets for new drug design [30]. This evidence concerns the gene SLC9A3 and coronary artery disorder.